Trial Profile
Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Trebananib (Primary)
- Indications Haemangiosarcoma
- Focus Therapeutic Use
- 16 Oct 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 16 Mar 2015 Status changed from suspended to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 08 Nov 2013 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.